Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma

PURPOSE: Standard frontline treatment of patients with metastatic renal cell carcinoma currently includes sunitinib. A barrier to long-term treatment with sunitinib includes the development of significant adverse effects, including diarrhea, hand-foot syndrome (HFS), and fatigue. This trial assessed...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Oncol
Главные авторы: Jonasch, Eric, Slack, Rebecca S., Geynisman, Daniel M., Hasanov, Elshad, Milowsky, Matthew I., Rathmell, W. Kimryn, Stovall, Summer, Juarez, Donna, Gilchrist, Troy R., Pruitt, Lisa, Ornstein, Moshe C., Plimack, Elizabeth R., Tannir, Nizar M., Rini, Brian I.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2018
Предметы:
ORIGINAL REPORTS
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804828/
https://ncbi.nlm.nih.gov/pubmed/29641297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.77.1485
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы